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GLAUCOMA OR OCULAR HYPERTENSION AS
AN ALTERNATIVE TO FILTRATION SURGERY 
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Holmstrom S4
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OBJECTIVES: Glaucoma is a condition affecting one 
or both eyes with raised intraocular pressure (IOP). IOP
reduction can prevent or slow progression of visual ﬁeld
loss. The objective of the analysis was to investigate the
four-year costs of bimatoprost 0.03% as an alternative to
ﬁltration surgery (FS) for glaucoma patients on maximum
tolerable medical therapy (MTMT) in Italy. METHODS:
A Markov model with monthly cycles based on effec-
tiveness and resource-use data from a clinical trial and
expert statements was designed. The trial covered 83
patients on MTMT. The model compared bimatoprost
with FS. In one model-arm patients began treatment with
bimatoprost. If a 30% reduction in IOP was not reached
using mono-therapy the patient proceeded with combi-
nation-therapy and eventually FS. In the other model-arm
FS was performed after the ﬁrst ophthalmologist visit. In
both arms treatment changes involved additional follow-
up visits besides the scheduled, an increasing proportion
needed pressure-lowering medication after FS and 40%
were operated in both eyes. Unit costs were obtained from
an Italian chart and tariffs review. The model analysed
four-year costs from a national Health care sector per-
spective. A 5% discount rate was used. RESULTS: The
4-year cost per patient in the bimatoprost arm was €3372
with visit costs and medications contributing the most. In
the FS arm four years costs were €4284 with the costs
being driven by primary surgery, secondary surgery, and
pressure-lowering medications needed post-surgery to
control IOP. CONCLUSIONS: The analysis indicates that
bimatoprost over a four year horizon is a cheaper alter-
native than FS. This result was strengthened by a thresh-
old sensitivity analysis showing that the FS price would
need to be reduced 73% before FS and bimatoprost were
equally costly. Italian ophthalmologists should therefore
consider bimatoprost as an alternative to FS.
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BURDEN OF ILLNESS OF INFLUENZA
Mychaskiw MA, Sankaranarayanan J
Purdue University, West Lafayette, IN, USA
OBJECTIVE: The purpose of this study was to determine
the burden of illness of inﬂuenza in the United States.
METHODS: Retrospective analysis was conducted of the
1999 portion of the Medical Expenditure Panel Survey.
Data was collected from a nationally representative
sample of 24,618 respondents and linked to data from
respondents’ medical care and health insurance providers
and employers. Data used in this study included medical
conditions, use and payments for medical care, and
employment information comprised of hourly earnings,
hours worked, and disability days. Inﬂuenza patients
were identiﬁed using ICD-9-CM codes (487.0–487.8).
Direct costs were calculated using patient and third-party
payments for inﬂuenza-related medical events. Indirect
costs were calculated for inﬂuenza patients who incurred
missed workdays using the human capital approach.
Sample estimates were weighted and projected to the pop-
ulation and 95 percent conﬁdence limits were calculated
using the Taylor expansion method. RESULTS: Ap-
proximately 6.38% (95% C.L. = 5.86%–6.91%) or
17,640,761 individuals experienced inﬂuenza and 2.50%
(95% C.L. = 2.22%–2.79%) or 6,920,976 individuals
experienced inﬂuenza resulting in missed workdays. Total
costs of inﬂuenza were $10,413,397,186. Direct costs
were $1,251,588,028. Ofﬁce-based medical provider
visits represented the highest proportion of direct 
costs, at $407,049,515 (mean = $64.56; 95% C.L. =
$54.45–$74.67). Home health care expenditures were
$265 million. Expenditures for inpatient stays, prescrip-
tion medications, and emergency department visits were
similar, at $189 million, $185 million, and $175 million,
respectively. Outpatient services represented the lowest
proportion of direct costs, at $31 million. Indirect costs
of inﬂuenza were $9,161,809,158 with mean indirect
costs of $1,325 per patient (95% C.L. = $1,130–$1,521).
CONCLUSIONS: Affecting more than 17 million indi-
viduals in the population with a total cost of $10.4
billion, the burden of illness of inﬂuenza was substantial.
With indirect costs accounting for nearly 90% of total
costs, inﬂuenza signiﬁcantly impacts the labor force
underscoring the importance of prevention to minimize
absenteeism and maintain productivity.
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INITIAL INSERTION OF A METAL STENT FOR
PALLIATION OF MALIGNANT BILIARY
OBSTRUCTION: A COST CONSEQUENCE
ANALYSIS FOR ENGLAND, FRANCE AND
SWEDEN
Verin N,Wenk-Lang A
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France
OBJECTIVE: Placement of a biliary stent (plastic or
metal) is a recognised palliative treatment for malignant
biliary obstruction. Metallic stents have a lower occlusion
rate and avoid reinterventions for exchange but are more
expensive. The objective of this analysis is to compare the
total costs at one year of metal versus plastic stent place-
ment. METHODS: A Markov model with a time horizon
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of 12 months and cycle lengths of 1 month was designed
to evaluate the cumulative costs over time of plastic and
metal stent. A meta-analysis of all published randomised
trials was performed to derive the transitional probabili-
ties for ﬁrst and second occlusion and for death. A
national health care perspective was adopted. Unit cost
data was obtained from available public sources in
France, Sweden and England. Resource use was derived
from expert opinions in each country. RESULTS: Initial
procedural costs were higher with metal than with plastic
stents: the cost difference was €953 for Sweden, €739 for
France and €653 for England. However, due to fewer
reinterventions for exchange, follow-up costs were sub-
stantially reduced with metal stents. In Sweden and
England, the cost break-even point was after 4 months
and for patients with longer survival, metal stents became
cost-saving. In France, the break-even point was after 5
months. At 12 months, the difference per patient cost in
favour of metal was €493 for France, €620 for England
and €1002 for Sweden. CONCLUSION: This analysis
demonstrates that initial metal stent placement can be a
cost-saving strategy, especially if the patient survives 
more than 4 to 5 months. The higher procedural cost 
with a metal stent is offset by a reduction in re-treatment
costs. Avoiding reinterventions will beneﬁt patients in
terms of quality of life and the health care system as a
whole.
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OBJECTIVES: With a prevalence of 10% asthma is the
most common chronic disease among children and ado-
lescents in Germany. Approaches to reduce the burden of
asthma comprise patient education as a well-recognised
and effective component that helps to improve self-
management skills. We determined whether a continuous
internet-based education programme (IEP) as an add-on
to traditional education improves health outcomes of
asthma patients (8–16 years) at a favourable beneﬁt-cost
ratio. METHODS: We performed a prospective cost-
beneﬁt analysis alongside a non-randomised trial. A total
of 438 patients in 34 study centres in Germany were
enrolled in the investigation. Study participants were
assigned to a control group and two intervention groups.
Patients in both intervention groups received traditional
patient education. In one group patients received addi-
tional self-management education through the IEP for the
duration of 6 months. At the initial visit and at 6 and 12
months health service utilisation data were collected.
RESULTS: Utilisation of various Health care services (e.g.
number of consultations, urgent medical examinations)
decreased signiﬁcantly in both intervention groups. In the
ﬁrst year after intervention traditional education realised
morbidity cost savings of 333 EUR per patient. Adding
the IEP provided incremental savings of €143. From a
payer perspective, the beneﬁt-cost ratio of the traditional
education programme was 0.45. Adding the IEP im-
proved the ratio (0.69). For patients with moderate or
severe asthma the beneﬁt-cost ratio were 1.07 and 1.42
(with IEP). In individuals who had experienced an emer-
gency visit due to asthma 6 months prior to the study
entry, the ratios were 1.11 and 1.21, respectively. CON-
CLUSIONS: As a supplementary to traditional asthma
education programmes, the IEP offers the potential to
realise incremental morbidity savings. Subgroup analyses
demonstrated that within 1-year morbidity cost savings
surpass the intervention costs in patients who belong to
risk groups.
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A HEALTH ECONOMIC EVALUATION OF N-3
POLYUNSATURATED FATTY ACIDS (PUFA) IN
THE SECONDARY PREVENTION AFTER MI 
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OBJECTIVES: Patients who survived an acute myocar-
dial infarction (MI) have an increased risk for subsequent
major cardiovascular events and cardiac (often sudden)
death. The use of highly puriﬁed omega-3 polyunsatu-
rated fatty acids (n-3 PUFAs) in addition to standard 
secondary prevention after MI was associated with a sig-
niﬁcant reduction in risk of sudden death. Our study
assessed the cost-effectiveness (CE) of adding n-3 PUFAs
treatment to the current secondary prevention treatment
after acute MI in Belgium. METHODS: Based on the clin-
ical outcomes of the GISSI-prevenzione study (MI, stroke,
revascularisation rate and mortality) a decision model
was built in DataTM Pro. Adding n-3 PUFAs to standard
treatment was compared to standard treatment alone in
patients with a recent history of MI (age = 59 years) from
the health care payer’s perspective. The time horizon 
of the model was 3.5 years (identical to the GISSI-
prevenzione study). The cost of non-fatal events was
based on Belgian literature data and the cost of cardiac
death on a patient chart review (n = 60). The unit cost of
n-3 PUFAs was €1.25. Life expectancy data for cardiac
disease were obtained from published sources and
adjusted to the Belgian population. Results are expressed
as cost (€) per life year gained (LYG). RESULTS: Treat-
ment with n-3 PUFAs results in 0.287 life years gained at
